Abstract

CircRNAs are covalently closed, single-stranded RNA that form continuous loops and play a crucial role in the initiation and progression of tumors. Cancer stem cells (CSCs) are indispensable for cancer development; however, the regulation of cancer stem cell-like properties in gastric cancer (GC) and its specific mechanism remain poorly understood. We elucidate the specific role of Circ-0075305 in GC stem cell properties. Circ-0075305 associated with chemotherapy resistance was identified by sequencing GC cells. Subsequent confirmation in both GC tissues and cell lines revealed that patients with high expression of Circ-0075305 had significantly better overall survival (OS) rates than those with low expression, particularly when treated with postoperative adjuvant chemotherapy for GC. In vitro and in vivo experiments confirmed that overexpression of Circ-0075305 can effectively reduce stem cell-like properties and enhance the sensitivity of GC cells to Oxaliplatin compared with the control group. Circ-0075305 promotes RPRD1A expression by acting as a sponge for corresponding miRNAs. The addition of LF3 (a β-catenin/TCF4 interaction antagonist) confirmed that RPRD1A inhibited the formation of the TCF4–β-catenin transcription complex through competitive to β-catenin and suppressed the transcriptional activity of stem cell markers such as SOX9 via the Wnt/β-catenin signaling pathway. This leads to the downregulation of stem cell-like property-related markers in GC. This study revealed the underlying mechanisms that regulate Circ-0075305 in GCSCs and suggests that its role in reducing β-catenin signaling may serve as a potential therapeutic candidate.

Circular RNA Circ0075305 hinders gastric cancer stem cells by indirectly increasing the expression of RPRD1A. In turn, RPRD1A disrupts TCF4-β-catenin complex formation and promotes downregulation of SOX9 transcription.

Details

Title
Circ-0075305 hinders gastric cancer stem cells by indirectly disrupting TCF4–β-catenin complex and downregulation of SOX9
Author
Chen, Qi-Yue 1 ; Xu, Kai-Xiang 1 ; Huang, Xiao-Bo 1 ; Fan, Deng-Hui 1 ; Chen, Yu-Jing 1 ; Li, Yi-Fan 1 ; Huang, Qiang 1 ; Liu, Zhi-Yu 1 ; Zheng, Hua-Long 1 ; Huang, Ze-Ning 1 ; Lin, Ze-Hong 1 ; Wang, Yu-Xiang 1 ; Yang, Jun-Jie 1 ; Zhong, Qing 1 ; Huang, Chang-Ming 1   VIAFID ORCID Logo 

 Fujian Medical University Union Hospital, Department of Gastric Surgery, Fuzhou, China (GRID:grid.411176.4) (ISNI:0000 0004 1758 0478); Fujian Medical University Union Hospital, Department of General Surgery, Fuzhou, China (GRID:grid.411176.4) (ISNI:0000 0004 1758 0478); Fujian Medical University, Key Laboratory of Ministry of Education of Gastrointestinal Cancer, Fuzhou, China (GRID:grid.256112.3) (ISNI:0000 0004 1797 9307) 
Pages
545
Publication year
2024
Publication date
2024
Publisher
Nature Publishing Group
e-ISSN
23993642
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3051760112
Copyright
© The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.